CS
CDAK

Credit Suisse’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Credit Suisse’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8
Closed – – 4467
2022
Q2 		$0 Buy
+8
New +$28 ﹤0.01% 4536

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse's CDAK Position: Q3 2022 in Review

Credit Suisse sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q3 2022, closing a stake of 8 shares.

Credit Suisse first reported a position in CDAK in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 48 funds tracked by Wall St. Rank hold CDAK as of Q3 2022.

  • Credit Suisse reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 8 Codiak BioSciences, Inc. Common Stock shares in Q3 2022.
  • Credit Suisse first reported a position in Codiak BioSciences, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Codiak BioSciences, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 48 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.